Zogenix delivery tech earns patent; Researchers find nanoparticles damage brain;

> Zogenix ($ZGNX) revealed that it was issued a patent on the biphasic pressure profile utilized by the company's proprietary DosePro Needle-free Delivery System. Release

> The hype around nanoparticles might not be all it's cracked up to be, according to research that saw a correlation of brain damage in rats inserted with micelles nanoparticles. A toxic positive charge on the nanoparticles' surface is reported to cause the damage. Story

> Tiny DNA pyramids, an engineered nanomedicine, might be a forthcoming defense in fighting the growing problem of antibiotic resistance. Story

Suggested Articles

J&J has new data that should convince regulators to clear its subcutaneous Darzalex in another indication—widening its edge over a Sanofi rival.

Genentech's Port Delivery System with ranibizumab matched Lucentis eye injections in a late-stage, wet age-related macular degeneration trial.

Honeywell aims to wean the industry of its glass habit with Aclar Edge, a new line of bottles and vials made with the company's patented plastic.